Sibutramine (Meridia) has two active metabolites that improve lipid profiles in addition to increasing thermogenesis and reducing appetite.
Phentermine is a sympathomimetic indicated for the short-term use of obesity. It suppresses appetite by acting on the hypothalamus. Orlistat decreases intestinal fat absorption.
Dronabinol activates cannabinoid type 1 (CB1) receptors and therefore appetite. Progestational agents such as megestrol acetate have also been shown to induce weight gain in patients.